Vendor Intelligence Report: LN Peptides

Published 3 Jul 2026. 26-page investigative report on who is behind LN Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 36 Finnrick lab tests, LN Peptides records 27 pass / 9 fail, for an overall pass rate of 75%. The record is product-specific rather than uniformly reassuring: retatrutide and tirzepatide are the most defensible LN choices in the tested catalog, while tesamorelin is the clear weak spot. The remaining tested products have too little depth to carry the same weight, and stricter Finnrick grading makes the weak tail more visible.

The report resolves LN's identity beyond the storefront. A contact identifier embedded in site infrastructure links the peptide brand to a named Xi'an exporter, overlapping personnel, a listed address, and sister storefronts. That is better than a blank shell, but it also exposes a gap between the older exporter footprint and the peptide brand's own verifiable history.

The most important credibility finding is the age claim. The public site presents a 15+ year/since-2013 story, while domain, certificate, archive, ICP, and copy-history records tell a more complicated timeline; one captured About Us page preserves conflicting age claims in the same text. For crypto-funded injectable purchases, longevity claims are not harmless decoration.

Operational risk clusters around the sales model: a broad multi-rep Telegram/WhatsApp network, crypto-only payment rails, and a vendor-maintained CHEATER page documenting fake reps, fake groups, copied photos, and lookalike sites. The report treats channel verification, vendor COA limitations, the tesamorelin forum flag, and the public endotoxin-assurance gap as practical buyer-risk items, not background color.

Inside the full report:

  • Per-product pass/fail rates, Finnrick rating trajectories, methodology-divergence charts, and Appendix A lab data for all 5 tested products
  • Corporate-linkage analysis across LN Peptides, the older Xi'an exporter, sister brands, address evidence, and personnel
  • Dated record package covering domain registration, certificate transparency, Wayback captures, ICP marker, and conflicting About Us copy
  • Telegram/WhatsApp sales-channel analysis with payment-rail review and buyer-verification checklist
  • CHEATER-page incident review covering fake reps, fake groups, copied photos, and lookalike websites
  • Vendor COA review, Janoshik access limitation, forum tesamorelin flag, and public endotoxin-assurance gap

Risk assessment

  • Misleading operating-history risk — high: LN Peptides markets 15+ years/since 2013, while lnpeptide.com was registered 2025-03-31, the parent ICP marker begins in 2017, and captured About Us copy contains conflicting 15-year and 13-year text.
  • Copycat / brand-confusion risk — high: The vendor's own CHEATER page documents 20+ impersonation incidents, and the multi-rep Telegram/crypto sales model leaves buyers dependent on careful channel verification.
  • Crypto-only payment recourse risk — high: LN Peptides lists USDT and BTC wallets but no chargeback-capable payment rail; scam, seizure, loss, or quality disputes depend on vendor goodwill.
  • Tesamorelin quality risk — high: Tesamorelin is fail-heavy in Finnrick data (9 tests, 3 pass / 6 fail; 40.96%) and an external forum report described cloudy reconstitution and an 84.3% fill result.
  • Public endotoxin-assurance gap concern — medium: LN Peptides publishes vendor-selected COAs, but field review did not find public endotoxin testing for injectable peptide batches.